Inmed pharmaceuticals files additional patent application for inm-901 in the treatment of neurodegenerative conditions including alzheimer's disease

Vancouver, british columbia--(newsfile corp. - october 28, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has filed an additional international patent application, under the patent cooperation treaty (pct), focused on the pharmaceutical composition and method of use for the proprietary small molecule drug candidate inm-901 for treating neurodegenerative diseases, including alzheimer's disease. this pct patent application encompasses several key components, including: treatment of neuronal disorders, particularly those associated with neurodegeneration; potential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations; and use in promoting neurite elongation and/or restoring neurite formation in damaged neurons.
INM Ratings Summary
INM Quant Ranking